Bosentan therapy for patients with severe Raynaud's phenomenon in systemic sclerosis.
作者信息
Hettema M E, Zhang D, Bootsma H, Kallenberg C G M
出版信息
Ann Rheum Dis. 2007 Oct;66(10):1398-9. doi: 10.1136/ard.2007.073684.
Abstract
摘要
相似文献
1
Bosentan therapy for patients with severe Raynaud's phenomenon in systemic sclerosis.波生坦治疗系统性硬化症伴严重雷诺现象的患者。
Ann Rheum Dis. 2007 Oct;66(10):1398-9. doi: 10.1136/ard.2007.073684.
2
Successful treatment of patients with severe secondary Raynaud's phenomenon with the endothelin receptor antagonist bosentan.内皮素受体拮抗剂波生坦成功治疗重度继发性雷诺现象患者。
Rheumatology (Oxford). 2006 Oct;45 Suppl 3:iii45-8. doi: 10.1093/rheumatology/kel290.
3
Treatment of severe Raynaud's phenomenon with bosentan in a patient with systemic sclerosis.
Rheumatology (Oxford). 2006 Jul;45(7):911-2. doi: 10.1093/rheumatology/kei129. Epub 2006 Mar 10.
4
Assessment of digital vascular structure and function in response to bosentan in patients with systemic sclerosis-related Raynaud's phenomenon.系统性硬化症相关雷诺现象患者中波生坦治疗后数字血管结构与功能的评估。
Rheumatology (Oxford). 2007 Feb;46(2):363-4. doi: 10.1093/rheumatology/kel383. Epub 2006 Nov 20.
5
Effect of the dual endothelin receptor antagonist bosentan on Raynaud's phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study.波生坦对继发于系统性硬化症的雷诺现象的疗效：一项双盲前瞻性、随机、安慰剂对照的初步研究。
Rheumatology (Oxford). 2010 Mar;49(3):583-7. doi: 10.1093/rheumatology/kep413. Epub 2009 Dec 29.
6
Successful treatment of severe Raynaud's phenomenon with bosentan in four patients with systemic sclerosis.波生坦成功治疗4例系统性硬化症患者的严重雷诺现象。
Rheumatology (Oxford). 2004 Nov;43(11):1454-6. doi: 10.1093/rheumatology/keh340.
7
Effect of treatment with iloprost with or without bosentan on nailfold videocapillaroscopic alterations in patients with systemic sclerosis.伊洛前列素联合或不联合波生坦治疗对系统性硬化症患者甲襞微血管镜改变的影响。
Mod Rheumatol. 2017 Jan;27(1):110-114. doi: 10.1080/14397595.2016.1192761. Epub 2016 Jun 16.
8
Endothelin receptor antagonist bosentan improves the dermal sclerosis in a patient with systemic sclerosis.内皮素受体拮抗剂波生坦改善系统性硬皮病患者的皮肤硬化。
Australas J Dermatol. 2012 May;53(2):e32-3. doi: 10.1111/j.1440-0960.2010.00719.x. Epub 2010 Nov 29.
9
Efficacy of bosentan in the treatment of Raynaud's phenomenon in patients with systemic sclerosis never treated with prostanoids.波生坦治疗从未接受过前列腺素类药物治疗的系统性硬化症患者雷诺现象的疗效。
Reumatismo. 2014 Mar 17;65(6):286-91. doi: 10.4081/reumatismo.2013.691.
10
No effects of bosentan on microvasculature in patients with limited cutaneous systemic sclerosis.波生坦对局限性皮肤型系统性硬化症患者微血管无影响。
Clin Rheumatol. 2009 Jul;28(7):825-33. doi: 10.1007/s10067-009-1157-4. Epub 2009 Apr 7.
引用本文的文献
1
Pharmacotherapy Options in the Management of Raynaud's Phenomenon.雷诺现象治疗中的药物治疗选择
Curr Treatm Opt Rheumatol. 2018 Sep;4(3):235-254. doi: 10.1007/s40674-018-0102-6. Epub 2018 Jul 4.
2
Expression of the oxygen-sensitive transcription factor subunit HIF-1α in patients suffering from secondary Raynaud syndrome.缺氧诱导因子-1α亚基在继发雷诺综合征患者中的表达。
Acta Pharmacol Sin. 2019 Apr;40(4):500-506. doi: 10.1038/s41401-018-0055-1. Epub 2018 Jul 10.
3
The safety of iloprost in systemic sclerosis in a real-life experience.伊洛前列素在真实世界经验中的系统性硬化症中的安全性。
Clin Rheumatol. 2018 May;37(5):1249-1255. doi: 10.1007/s10067-018-4043-0. Epub 2018 Feb 22.
4
Digital ulcers in scleroderma patients: A retrospective observational study.硬皮病患者的指端溃疡：一项回顾性观察研究。
Int J Immunopathol Pharmacol. 2016 Jun;29(2):180-7. doi: 10.1177/0394632015606846. Epub 2015 Dec 18.
5
Endothelin Receptors Expressed by Immune Cells Are Involved in Modulation of Inflammation and in Fibrosis: Relevance to the Pathogenesis of Systemic Sclerosis.免疫细胞表达的内皮素受体参与炎症调节和纤维化过程：与系统性硬化症发病机制的相关性
J Immunol Res. 2015;2015:147616. doi: 10.1155/2015/147616. Epub 2015 May 18.
6
Severe digital necrosis in a 4-year-old boy: primary Raynaud's or jellyfish sting.一名4岁男孩的严重手指坏死：原发性雷诺现象还是水母蜇伤。
BMJ Case Rep. 2013 Nov 18;2013:bcr2013201478. doi: 10.1136/bcr-2013-201478.
7
Iontophoresis of endothelin receptor antagonists in rats and men.内皮素受体拮抗剂在大鼠和人体中的经皮离子导入。
PLoS One. 2012;7(7):e40792. doi: 10.1371/journal.pone.0040792. Epub 2012 Jul 13.
8
Advances in the treatment of Raynaud's phenomenon.雷诺现象治疗的进展。
Vasc Health Risk Manag. 2010 Mar 24;6:167-77. doi: 10.2147/vhrm.s4551.
9
Targeted therapy for systemic sclerosis: how close are we?系统性硬皮病的靶向治疗：我们离目标还有多远？
Nat Rev Rheumatol. 2010 May;6(5):269-78. doi: 10.1038/nrrheum.2010.48. Epub 2010 Apr 13.
10
No effects of bosentan on microvasculature in patients with limited cutaneous systemic sclerosis.波生坦对局限性皮肤型系统性硬化症患者微血管无影响。
Clin Rheumatol. 2009 Jul;28(7):825-33. doi: 10.1007/s10067-009-1157-4. Epub 2009 Apr 7.
本文引用的文献
1
Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.系统性硬化症中的指端溃疡：通过口服内皮素受体拮抗剂波生坦治疗进行预防
Arthritis Rheum. 2004 Dec;50(12):3985-93. doi: 10.1002/art.20676.
2
Endothelin and endothelin receptor antagonists in systemic rheumatic disease.内皮素及内皮素受体拮抗剂在系统性风湿性疾病中的作用
Arthritis Rheum. 2003 May;48(5):1190-9. doi: 10.1002/art.10895.
3
Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.测量硬皮病和雷诺现象患者的疾病活动度和功能状态。
Arthritis Rheum. 2002 Sep;46(9):2410-20. doi: 10.1002/art.10486.
4
Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study.口服伊洛前列素治疗系统性硬化症继发雷诺现象：一项多中心、安慰剂对照、剂量比较研究。
Br J Rheumatol. 1998 Sep;37(9):952-60. doi: 10.1093/rheumatology/37.9.952.
5
Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.口服伊洛前列素治疗系统性硬化症继发雷诺现象患者：一项多中心、安慰剂对照、双盲研究。
Arthritis Rheum. 1998 Apr;41(4):670-7. doi: 10.1002/1529-0131(199804)41:4<670::AID-ART14>3.0.CO;2-I.
6
7
Reproducibility of the finger cooling test.手指冷却试验的可重复性。
Microvasc Res. 1993 Jan;45(1):65-73. doi: 10.1006/mvre.1993.1006.
8
Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study.静脉输注伊洛前列素治疗系统性硬化症继发雷诺现象。一项多中心、安慰剂对照、双盲研究。
Ann Intern Med. 1994 Feb 1;120(3):199-206. doi: 10.7326/0003-4819-120-3-199402010-00004.
9
Once daily felodipine in patients with primary Raynaud's phenomenon.
Eur J Clin Pharmacol. 1991;40(3):313-5. doi: 10.1007/BF00315217.
10
Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.静脉注射伊洛前列素治疗系统性硬化症继发的雷诺现象和缺血性溃疡。
J Rheumatol. 1992 Sep;19(9):1407-14.
Zotero 插件